DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year.
SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $50
SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $54 to $50.
